Table 4.

Treatment-specific SNP effects on short-term weight loss and diabetes risk.

SNP	Minor (major) allele	Lifestyle		Metformin		Placebo
6m Weight Loss (kg/allele)		Coefficient(SE)	P-value	Coefficient(SE)	P-value	Coefficient(SE)	P-values
N		1041		1024		1020
rs17066856	C(T)	-0.01 (0.33)	0.980	0.50 (0.27)	0.064	-0.33 (0.27)	0.214
rs9966412	A(G)	0.15 (0.32)	0.640	0.54 (0.26)	0.034	-0.28 (0.25)	0.258
rs17066859	A(G)	0.35 (0.39)	0.358	0.71 (0.30)	0.016	-0.36 (0.31)	0.245
rs8091237	G(C)	-0.36 (0.32)	0.259	0.40 (0.24)	0.094	0.32 (0.26)	0.215
rs17066866	T(A)	1.48 (0.53)	0.006	0.54 (0.43)	0.207	0.05 (0.45)	0.917
rs7240064	T(C)	-0.11 (0.34)	0.758	0.29 (0.26)	0.266	0.64 (0.28)	0.024
2yr Weight Loss (kg/allele)		Coefficient(SE)	P-value	Coefficient(SE)	P-value	Coefficient(SE)	P-value
N		999		1004		1012
rs12970134	A(G)	-0.75 (0.43)	0.081	0.20 (0.31)	0.513	0.24 (0.32)	0.450
rs17066866	T(A)	2.25 (0.77)	0.004	0.10 (0.60)	0.866	0.02 (0.60)	0.979
Diabetes Risk		HR(95% CI)	P-value	HR(95% CI)	P-value	HR(95% CI)	P-value
N		1079		1073		1082
rs17066829	A(T)	0.80 (0.64-1.00)	0.054	1.06 (0.89-1.27)	0.514	1.09 (0.92-1.29)	0.309

All analyses are adjusted for baseline age, sex, ethnicity and treatment assignment.